



Drug Discovery 2017

ACC, LIVERPOOL

3rd - 4th October 2017

FROM MOLECULE TO MAN: RIGHT DOSE, FIRST TIME
Wednesday 4th October 2017: HALL 1B

Session Chairs

Pinky Dua (Pfizer) & Piet Van der Graaf (Leiden University)

Taking a molecule from laboratory to the human subject is a key step in drug development when potential new medicines are given to humans for the first time. It is an exciting phase to unravel how the molecule behaves in human but also comes with many challenges that need to be considered and evaluated prior to First in Human study. The safety and well-being of the subjects, whether they are healthy individuals or patients must always be a priority while designing these studies.

Understanding of the mechanism, confidence in translation from non-clinical data to the clinic, choosing relevant biomarkers, different considerations based on the modality of the molecule (small molecule, large molecule) being studied and regulatory guidance are all important factors to consider. Predicting the right dose of a drug, at the right time, to the right patient population is still a key challenge.

In this session, speakers from leading academic and pharmaceutical institutions will cover these aspects and talk about the state-of-the-art that enables improved translatability of drug therapies from the laboratory to the patient.

CONFIRMED SPEAKERS

Meindert Danhof (University of Leiden) - **Session Keynote**

Amin Rostami (University of Manchester)

Neil Benson (Certara)

Mark Fidock (AstraZeneca)

Mario van der Stelt (Leiden Institute for Chemistry)

Stefano Zamuner (GlaxoSmithKline)

Pinky Dua (Pfizer)

Follow us on Twitter [@ELRIG_UK](https://twitter.com/ELRIG_UK) for all the latest updates on ELRIG events & news.

www.elrig.org